Clinical trials: Prostate Disease
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Prostate Cancer
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
This study aims to determine whether early treatment with zoledronic acid, that is given during the early phase of advanced prostate cancer, will be more efficacious than delayed treatment
- Trial name
- NCT00242567
- Testing
- Zoledronic Acid, Androgen Deprivation Therapy (ADT)
- Where
- 27 sites in Australia, Brazil and 8 more
- Volunteers
- 522 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Safety Evaluation of ExAblate MRgFUS for Prostate Cancer
Evaluate the safety, compatibility and imaging quality of the ExAblate MRgFUS system.
- Trial name
- NCT00811265
- Testing
- ExAblate MRgFUS for prostate cancer
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- InSightec
Benign Prostatic Hyperplasia (BPH), Enlarged Prostate
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
This completed study evaluated the safety and efficacy of two dose levels of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) versus finasteride.
- Trial name
- NCT00759135
- Testing
- 2.5 mg NX-1207, 0.125 mg NX-1207, finasteride
- Where
- 30 sites in United States
- Volunteers
- 85 people
- Sponsor
- Nymox Corporation
Recurrent Prostate Cancer
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)
For the treatment of locally recurrent prostate cancer following failed external beam radiation therapy (EBRT)
- Trial name
- STAR (NCT00772317)
- Testing
- High Intensity Focused Ultrasound
- Where
- 16 sites in United States, Canada
- Volunteers
- 117 people
- Sponsor
- SonaCare Medical
Localized Low-Intermediate Risk Prostate Cancer
Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study
The hypothesis of this feasibility study is that focal treatment with ExAblate MRgFUS has the potential to be a safe and effective non-invasive treatment for low to intermediate risk, organ-confined prostate cancer involving low…
- Trial name
- NCT01226576
- Testing
- MRgFUS Treatment
- Where
- 5 sites in Canada, Israel and 3 more
- Volunteers
- 8 people
- Sponsor
- InSightec
Prostate Cancer
Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-NYM032 in addition to best supportive/best standard of care versus patients treated with…
- Trial name
- NCT07795268
- Testing
- 177Lu-NYM032 injection, Best supportive/best standard of care
- Volunteers
- 600 people
- Sponsor
- Norroy Bioscience Co., LTD
Prostatic Hyperplasia
Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
Patient-based surveys will be conducted to evaluate the drivers of medication adherence in patients treated with either 5-alpha-reductase inhibitor (5ARI) therapy, alpha-blocker (AB) therapy, or combination therapy for enlarged…
- Trial name
- NCT01390870
- Testing
- 5ARI or AB or Combination Therapy (5ARI + AB)
- Volunteers
- 400 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Interest of a Systematic Assessment of the Treatment of LUTS in the Management of BPH
The high level of unsatisfactory outcome observed in patients treated for LUTS associated with BPH with respect to the different existing therapeutic options strongly emphasizes the need for treatment optimisation in daily…
- Trial name
- UROEVAL (NCT03179670)
- Where
- France
- Volunteers
- 625 people
- Sponsor
- RECORDATI GROUP
Prostate Cancer, Prostatic Neoplasms
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC.
- Trial name
- NCT06925737
- Testing
- Ifinatamab deruxtecan, Docetaxel, Prednisone
- Where
- 303 sites in United States, Argentina and 33 more
- Volunteers
- 1,440 people
- Sponsor
- Merck Sharp & Dohme LLC
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
A post-market, non-interventional, two-arm, long-term follow-up study of patients previously enrolled in the WATER Study (NCT02505919) - which was a prospective multi-centre randomized blinded study comparing Aquablation of the…
- Trial name
- NCT04658056
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- PROCEPT BioRobotics
Prostatic Neoplasms
A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
Researchers have designed a study medicine called MK-5684 as a new way to treat prostate cancer. The purpose of this study is to learn what happens to MK-5684 in a person's body over time (a pharmacokinetic or PK study).
- Trial name
- NCT06554639
- Testing
- MK-5684, Prednisone, Fludrocortisone acetate
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Lower Urinary Tract Symptoms, Prostatic Hyperplasia
A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH
The study will examine the efficacy,safety and tolerability of combination therapy of tamsulosin and solifenacin compared to placebo and monotherapy of tamsulosin and solifenacin in the treatment of males with LUTS associated…
- Trial name
- SATURN (NCT00510406)
- Testing
- tamsulosin hydrochloride, solifenacin succinate
- Where
- 98 sites in Austria, Czechia and 14 more
- Volunteers
- 919 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
A Phase 2, 2 part trial to evaluate the safety and efficacy of galeterone in castration resistant prostate cancer (CRPC) patients.
- Trial name
- ARMOR2 (NCT01709734)
- Testing
- galeterone
- Where
- 23 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- LTN PHARMACEUTICALS, INC.
Prostate Cancer
DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
The primary objective of this study is: To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer The secondary objectives of this study are: To…
- Trial name
- NCT00273338
- Testing
- calcitriol, docetaxel
- Where
- 222 sites in United States, Canada and 7 more
- Volunteers
- 1,200 people
- Sponsor
- Novacea
Prostate Cancer
Vidaza to Restore Hormone Thx Prostate
The purpose of this research study is to find out what effects (good and bad) Vidaza has on patients with prostate cancer. This investigational drug is not approved by the Food and Drug Administration (FDA) for the treatment of…
- Trial name
- NCT00384839
- Testing
- azacitidine for injectable suspension
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- US Oncology Research
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
- Trial name
- NCT06788509
- Testing
- JNJ-75348780, JNJ-67856633, JNJ-54179060
- Where
- 39 sites in Australia, Belgium and 13 more
- Volunteers
- 120 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancers, Breast Cancer
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II.
- Conditions
- Prostate Cancers, Breast Cancer, Lung Cancers, Ovarian Cancer
- Trial name
- ADVICE (NCT06926075)
- Testing
- A novel hGIIA-Vimentin Inhibitor, Dose expansion
- Where
- 3 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Filamon LTD
Adenocarcinoma of the Prostate
Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
This single arm, multicenter, open-label, Phase II study will enroll chemotherapy-naive participants with metastatic, histologically-confirmed adenocarcinoma of the prostate (stage M1 D2).
- Trial name
- NCT00520481
- Testing
- IMC-A12 (Cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).
- Trial name
- ARMOR3-SV (NCT02438007)
- Testing
- Galeterone, Enzalutamide
- Where
- 117 sites in United States, Australia and 6 more
- Volunteers
- 953 people
- Sponsor
- LTN PHARMACEUTICALS, INC.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.